Each week we highlight five things affecting the life sciences industry. Here’s the latest.
- Small companies led the way with 55 new drug and biologic approvals, reflecting a trend of biotechs resisting buyouts and opting to market their products independently, reports Fierce Pharma.
- Significant treatments were approved for a range of conditions, including metabolic disorders and chronic respiratory diseases.
- As reported by BioSpace, industry sentiment is low as biopharma heads into the 2025 J.P. Morgan Healthcare Conference, hoping for mergers and acquisitions to lift spirits.
- Last year had fewer big deals and multiple clinical failures, contributing to the pessimism in the sector.
- The U.S. Food and Drug Administration proposes a minimum 5% weight-loss requirement for investigational obesity therapies to establish efficacy, reports BioSpace.
- New guidelines aim to regulate the increasingly crowded obesity treatment market and ensure safety and effectiveness in drug development.
- The FDA issued draft guidance to address transparency and bias in artificial intelligence-enabled medical devices, reports MedTech Dive.
- Recommendations include that manufacturers have a post-market performance monitoring plan in place because the performance of AI-enabled devices can change or degrade over time.
- Pharmaceutical companies are increasingly looking to China for partnerships and deals, despite regulatory uncertainties, according to BioSpace.
- China’s evolving life sciences policies are making the region more attractive for biopharma investments, focusing on innovation and data transparency.
For more insights in life sciences, check out RSM’s industry outlook.
Leave a Reply